| Predicate |
Object |
| contentType |
Journal Article |
| endingPage |
963 |
| issn |
1470-2045 |
| issueIdentifier |
10 |
| pageRange |
962-963 |
| publicationName |
The Lancet. Oncology |
| startingPage |
962 |
| bibliographicCitation |
Girard N. Crizotinib in ALK-positive lung cancer. Lancet Oncol. 2012 Oct;13(10):962–3. doi: 10.1016/s1470-2045(12)70375-3. PMID: 22954506. |
| creator |
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bc45866352da367cb978a67894f3b0f4 |
| date |
201210 |
| identifier |
https://doi.org/10.1016/s1470-2045%2812%2970375-3
https://pubmed.ncbi.nlm.nih.gov/22954506 |
| isPartOf |
https://portal.issn.org/resource/ISSN/1470-2045
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/27004 |
| language |
English |
| source |
https://pubmed.ncbi.nlm.nih.gov/
https://www.crossref.org/ |
| title |
Crizotinib in ALK-positive lung cancer |
| discusses |
http://id.nlm.nih.gov/mesh/M0457532
http://id.nlm.nih.gov/mesh/M0553416
http://id.nlm.nih.gov/mesh/M0018233
http://id.nlm.nih.gov/mesh/M0018226
http://id.nlm.nih.gov/mesh/M0328256
http://id.nlm.nih.gov/mesh/M0493054
http://id.nlm.nih.gov/mesh/M0228330 |
| hasPrimarySubjectTerm |
http://id.nlm.nih.gov/mesh/D011720Q000627
http://id.nlm.nih.gov/mesh/D008175Q000188
http://id.nlm.nih.gov/mesh/D002289Q000188
http://id.nlm.nih.gov/mesh/D020794Q000037
http://id.nlm.nih.gov/mesh/D011725Q000627
http://id.nlm.nih.gov/mesh/D047428Q000627 |
| hasSubjectTerm |
http://id.nlm.nih.gov/mesh/D000077548
http://id.nlm.nih.gov/mesh/D006801
http://id.nlm.nih.gov/mesh/D000077547
http://id.nlm.nih.gov/mesh/D008297
http://id.nlm.nih.gov/mesh/D005260 |
| discussesAsDerivedByTextMining |
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11626560
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8366 |